Why Alzheimer's drugs may miss the clinical mark

Reassessing the foundations of Alzheimer's care

For many families navigating the difficult journey of Alzheimer's disease, the promise of new medications has often felt like a glimmer of hope in a long, dark tunnel. However, a comprehensive Cochrane systematic review published in May 2026 has cast a shadow of doubt over a primary class of drugs once thought to be the answer.

These medications - amyloid-beta-targeting monoclonal antibodies - work by clearing amyloid beta, a protein that clumps into plaques in the brains of those with the condition. While the scientific community has long focused on these plaques as a major pathological hallmark of the disease, this massive analysis involving 17 clinical trials and more than 20,000 participants (20,342 in total) suggests that removing them may not actually help patients live more independent or clearer lives.

The review suggests that while these drugs are technically successful at clearing the brain of amyloid, the clinical benefit to the human being behind the diagnosis remains marginal at best. For many doctors and patients, this raises a profound question: if a drug clears the plaque but the patient continues to lose their sense of self at nearly the same rate, is the treatment truly working?

This shift in perspective is not just about data points; it is about the real-world experience of spouses, children, and patients who are looking for more than just a cleaner brain scan. They are looking for more time, more recognition, and more moments of connection.

It is worth noting that the Cochrane review has not gone unchallenged. Several prominent neurologists and dementia researchers have raised methodological concerns, arguing that the review problematically pools multiple first-generation antibodies that were abandoned after failing to show benefit - such as bapineuzumab, crenezumab, and solanezumab - alongside newer, regulatory-approved agents such as lecanemab and donanemab, which have demonstrated measurable slowing of decline in large individual trials. Critics argue this conflation inevitably dilutes the signal from the drugs that have actually changed clinical practice.

Understanding the risks of brain swelling and bleeding

Perhaps the most concerning aspect of the recent findings is the evidence regarding safety. The review highlights a phenomenon known as Amyloid-Related Imaging Abnormalities, or ARIA. This condition involves:

• ARIA-E - brain swelling (edema or effusion)
• ARIA-H - microhemorrhages and superficial siderosis (hemorrhage)

For a patient already dealing with the vulnerability of a neurodegenerative disease, these side effects are not merely technical complications; they represent a significant physical burden. Importantly, the Cochrane analysis found that in many cases these changes appeared only on brain scans without obvious symptoms - though the long-term consequences remain unclear, as reporting of symptoms was inconsistent across the included trials.

When we look at the biology, the process of removing these plaques can trigger an inflammatory response. The immune system's reaction to the drug can cause localised inflammation and fluid accumulation in brain tissue. These risks are not rare:

• ARIA-E rates ranged from approximately 13% (lecanemab) to over 30% (aducanumab) depending on the specific agent
• ARIA-H rates were generally in the range of 17-20% across trials

Is it right to expose a loved one to the potential of brain microhemorrhages for a clinical improvement that may be so small it is barely perceptible in their daily routine? These are the heavy conversations happening in clinics today, as doctors and families weigh the hope of innovation against the reality of patient safety.

The threshold of meaningful clinical benefit

In the world of clinical research, there is a critical difference between a result being statistically significant and clinically meaningful. A drug might technically slow down a decline on a paper-and-pencil test, but if that change doesn't help a person remember their grandchildren's names or keep them from getting lost in their own neighbourhood, we have to ask if the threshold for success has been met.

The Cochrane review concludes that for the vast majority of patients in these trials, the improvements fell short of what would actually change their quality of life. The lead author, neurologist and epidemiologist Francesco Nonino, stated that while early trials found statistically significant results, it is essential to distinguish between statistical significance and genuine clinical relevance for patients.

This realisation is difficult to process, especially given the years of effort and billions of dollars invested in the amyloid hypothesis. However, science is a process of refinement. By acknowledging that this class of drugs may not be the definitive answer, we open the door to exploring other pathways.

What comes next: alternative research pathways

Researchers are already investigating a range of alternative targets that move beyond amyloid. These include:

• Tau protein tangles - neurofibrillary tangles that correlate closely with cognitive decline
• Neuroinflammation - targeting the brain's inflammatory processes that may accelerate damage
• Metabolic and vascular health - addressing cardiovascular risk factors known to contribute to dementia
• Synaptic protection - preserving the connections between neurons that underpin memory and cognition
• Gut-brain axis research - emerging evidence linking the microbiome to neurodegeneration

Each of these pathways represents a fundamentally different theory of what drives Alzheimer's progression - and why the amyloid hypothesis, despite decades of investment, may have been only a partial picture of a far more complex disease.

How patients and families can navigate the current landscape

Given the uncertainty highlighted by this review, it is reasonable to feel confused about what the evidence means in practice. A few considerations can help:

Ask your neurologist specifically which drug is being proposed. The evidence profile varies considerably between individual agents. Lecanemab and donanemab, for example, have shown measurable slowing of decline in large phase 3 trials; older, abandoned agents have not. These are not interchangeable.

Understand your ARIA risk. Patients who carry the APOE ε4 gene variant face meaningfully higher rates of ARIA complications. Genetic testing and MRI monitoring protocols should be part of any discussion about starting treatment.

Weigh benefit against daily life impact. The question is not only whether a drug slows decline on a rating scale, but whether that change is perceptible in the person's real-world functioning - in conversations, independence, and quality of life.

Consider the full care picture. Current evidence continues to support the value of physical exercise, cognitive engagement, sleep quality, and cardiovascular risk management as meaningful contributors to brain health - none of which carry the side-effect profile of immunotherapy.

Moving toward a more holistic approach

As we move forward, the focus must remain on the patient as a whole person, not just a set of symptoms or a collection of plaques. This review serves as a reminder that the brain is an incredibly delicate ecosystem. Intervening with powerful medications requires a level of precision that we are still striving to perfect.

Families should feel empowered to ask their neurologists about the specific trade-offs of these treatments - including which specific drug is being proposed, since the evidence profile varies considerably between individual agents - ensuring they have the full picture of both the limited benefits and the potential for serious brain risks.

The path to a cure is rarely a straight line. While these findings may feel like a setback, they are a vital part of the journey. They guide us toward asking harder questions and push us toward new, perhaps more effective, ways of supporting those with Alzheimer's. In the meantime, the value of compassionate care, social engagement, and supporting the dignity of every patient remains as important as any laboratory breakthrough. We continue to search, but we do so with eyes wide open to the complexities of the human mind and the safety of those we seek to heal.